COAG — Hemab Therapeutics Holdings, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 2114044 ·
Last close
$39.06
Market Cap
$1.83B
52W High
$55.42
52W Low
$23.00
ADV30
477,840
Next earnings
2026-11-10
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -29,758,000 -27,304,000 442,712,000 239,149,000 13,443,000
Jun 2026 0 — -26,079,000 -24,150,000 467,781,000 237,366,000 13,510,000
Mar 2026 0 — -23,612,000 -22,687,000 175,258,000 49,860,000 373,876,000
Dec 2025 0 — -20,447,000 -19,333,000 194,783,000 87,974,000 371,418,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-89,226,000
Investing CF
$-190,170,000
Financing CF
$473,556,000
CapEx
$-185,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.28
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-255,999,000
Inventory
—
Receivables
$1,205,000
ST Investments
$191,089,000
EBIT TTM
$-99,896,000
Pretax Income TTM
$-92,811,000
Interest Exp TTM
—
Analysts
7

Annual Trend (SEC EDGAR, last 2y)

Revenues vs Net Income (last 2y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -70,119,000 -63,913,000 194,783,000 371,418,000 -176,635,000 -61,475,000
Dec 2024 0 -50,383,000 -48,707,000 96,278,000 211,551,000 -115,273,000 -45,592,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$467,781,000
Forward EPS
$-2.65

Peers — same industry

TickerNameMarket CapLastDaily %
MAZE Maze Therapeutics, Inc. $1.80B $32.87 —
REPL Replimune Group, Inc. $1.87B $19.69 —
BCRX BIOCRYST PHARMACEUTICALS INC $1.93B $7.50 —
RXRX RECURSION PHARMACEUTICALS, INC. $1.69B $2.72 —
LYCA Lycia Therapeutics, Inc. $1.61B $30.92 —

News headlines (Yahoo Finance, 1h cache)

Hemab Therapeutics Holdings Inc (COAG) (Q3 2026) Earnings Call Highlights: Pivotal SOLARA Trial ...
2026-11-11 23:03 · Yahoo
Hemab Therapeutics to Participate in Upcoming Investor Conferences
2026-11-11 12:00 · Yahoo
Hemab (COAG) Q3 2026 Earnings Call Transcript
2026-11-10 19:31 · Yahoo
What Hemab Therapeutics (COAG) Said on Its Q3 Earnings Call
2026-11-10 15:15 · Yahoo
Hemab Therapeutics Initiates SOLARA, a Pivotal Phase 3 Trial of Sutacimig in Glanzmann Thrombasthenia
2026-11-09 12:00 · Yahoo
Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the 68th ASH Annual Meeting and Exposition
2026-11-04 14:05 · Yahoo
Hemab Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 10, 2026
2026-11-03 12:00 · Yahoo
Hemab Therapeutics Holdings (COAG) Joins Russell Indices, Is The Stock Still Trading At A Discount?
2026-09-29 01:07 · Yahoo
Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert
2026-09-24 20:01 · Yahoo
Hemab Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of HMB-003, an Investigational Therapy for the Management of Heavy Menstrual Bleeding
2026-09-17 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.